drugset / Trial / NCT04039217
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
Non-randomizedSequentialOpen-labelBasic science
Summary
The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how long it persists in different body compartments, including mucosal tissues, as it may be considered for PrEP or PEP regimens in the future.
Timeline
- Start
- 2019-09-30
- Primary completion
- 2020-08-28
- Completion
- 2020-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bictegravir | Small molecule | — | Oral |
| Subject | emtricitabine | Other / unclassified | — | Oral |
| Subject | tenofovir alafenamide | Small molecule | — | Oral |